Literature DB >> 21900532

High incidence of severe influenza among individuals over 50 years of age.

Anna J X Zhang1, Kelvin K W To, Herman Tse, Kwok-Hung Chan, Kun-Yuan Guo, Can Li, Ivan F N Hung, Jasper F W Chan, Honglin Chen, Sidney Tam, Kwok-Yung Yuen.   

Abstract

Age-specific epidemiological data on asymptomatic, symptomatic, and severe infections are essential for public health policies on combating influenza. In this study, we incorporated data on microbiologically confirmed infections and seroprevalence to comprehensively describe the epidemiology of pandemic H1N1 2009 influenza. Seroprevalence was determined from 1,795 random serum samples collected in our hospital in January 2007 (before the first wave of the pandemic) and March 2010 (after the second wave). Data on microbiologically confirmed infection and severe cases were obtained from the Centre for Health Protection in Hong Kong. Severe cases were most common in the 51- to 60-year-old age group. The microbiologically confirmed incidence rate was highest for children aged ≤10 years and dropped sharply for the adult population (ρ = -1.0; P < 0.01), but the incidence rate for severe disease was highest for the 51- to 60-year-old age group. For the 51- to 60-year-old age group, the seroprevalence was similar to that for the younger age groups, but the proportion of severe cases relative to seroprevalence was significantly higher than that for 11- to 50-year-old age groups. As judged from the percentage of specimens positive for other respiratory viruses compared with that for pandemic H1N1 virus, the impact of symptomatic disease due to pandemic H1N1 virus was higher than that for other respiratory viruses in people aged ≤50 years. In conclusion, the 51- to 60-year-old age group, which had the highest overall incidence and the highest rate of severe disease but is currently not considered by the World Health Organization to be an at-risk group, should be prioritized for influenza vaccination in areas where universal influenza vaccination is not practiced.

Entities:  

Mesh:

Year:  2011        PMID: 21900532      PMCID: PMC3209033          DOI: 10.1128/CVI.05357-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  52 in total

1.  2009 pandemic influenza A(H1N1) virus in Scotland: geographically variable immunity in Spring 2010, following the winter outbreak.

Authors:  W E Adamson; S Maddi; C Robertson; S McDonagh; P J Molyneaux; K E Templeton; W F Carman
Journal:  Euro Surveill       Date:  2010-06-17

2.  Serological surveillance of 2009 H1N1 influenza in China.

Authors:  Peng Yang; Weixian Shi; Lili Tian; Shuang Li; Li Zhang; Fang Huang; Quanyi Wang
Journal:  Int J Infect Dis       Date:  2010-12-09       Impact factor: 3.623

3.  Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October - December 2009.

Authors:  J McVernon; K Laurie; T Nolan; R Owen; D Irving; H Capper; C Hyland; H Faddy; L Carolan; I Barr; A Kelso
Journal:  Euro Surveill       Date:  2010-10-07

4.  Sero-immunity and serologic response to pandemic influenza A (H1N1) 2009 virus in Hong Kong.

Authors:  Gannon C Mak; Perrin W W Choy; W Y Lee; Ann H Wong; K C Ng; Wilina Lim
Journal:  J Med Virol       Date:  2010-11       Impact factor: 2.327

5.  Serologic survey of pandemic influenza A (H1N1 2009) in Beijing, China.

Authors:  Li-li Tian; Wei-xian Shi; Xing-huo Pang; Shu-juan Cui; Dai-tao Zhang; Quan-yi Wang
Journal:  Prev Med       Date:  2010-11-01       Impact factor: 4.018

6.  Epidemiology of 2009 pandemic influenza A (H1N1) in the United States.

Authors:  Michael A Jhung; David Swerdlow; Sonja J Olsen; Daniel Jernigan; Matthew Biggerstaff; Laurie Kamimoto; Krista Kniss; Carrie Reed; Alicia Fry; Lynnette Brammer; Jacqueline Gindler; William J Gregg; Joseph Bresee; Lyn Finelli
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 9.079

Review 7.  Seroprevalence to influenza A(H1N1) 2009 virus--where are we?

Authors:  Eeva Broberg; Angus Nicoll; Andrew Amato-Gauci
Journal:  Clin Vaccine Immunol       Date:  2011-06-08

8.  Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation.

Authors:  Marc Baguelin; Katja Hoschler; Elaine Stanford; Pauline Waight; Pia Hardelid; Nick Andrews; Elizabeth Miller
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

9.  Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai population.

Authors:  Hatairat Lerdsamran; Chakrarat Pittayawonganon; Phisanu Pooruk; Anek Mungaomklang; Sopon Iamsirithaworn; Prasert Thongcharoen; Uraiwan Kositanont; Prasert Auewarakul; Kulkanya Chokephaibulkit; Sineenat Oota; Warin Pongkankham; Patummal Silaporn; Supaloek Komolsiri; Pirom Noisumdaeng; Tawee Chotpitayasunondh; Chariya Sangsajja; Witthawat Wiriyarat; Suda Louisirirotchanakul; Pilaipan Puthavathana
Journal:  PLoS One       Date:  2011-01-25       Impact factor: 3.240

10.  Case fatality ratio of pandemic influenza.

Authors:  Hiroshi Nishiura
Journal:  Lancet Infect Dis       Date:  2010-07       Impact factor: 25.071

View more
  13 in total

1.  The Management of the 2009 pandemic Influenza A H1N1 virus infection.

Authors:  Kelvin K W To; Kwok-Yung Yuen
Journal:  J Thorac Dis       Date:  2012-02       Impact factor: 2.895

2.  Concerns for low coverage of influenza vaccination in middle-aged adults.

Authors:  Shui-Shan Lee; Edwin H F Leung; Ngai-Sze Wong
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

3.  Differential pathological and immune responses in newly weaned ferrets are associated with a mild clinical outcome of pandemic 2009 H1N1 infection.

Authors:  Stephen S H Huang; David Banner; Norbert Degousee; Alberto J Leon; Louling Xu; Stephane G Paquette; Thirumagal Kanagasabai; Yuan Fang; Salvatore Rubino; Barry Rubin; David J Kelvin; Alyson A Kelvin
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

Review 4.  Two years after pandemic influenza A/2009/H1N1: what have we learned?

Authors:  Vincent C C Cheng; Kelvin K W To; Herman Tse; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

5.  Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB/c mice.

Authors:  Anna J X Zhang; Can Li; Kelvin K W To; Hou-Shun Zhu; Andrew C Y Lee; Chuan-Gen Li; Jasper F W Chan; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2014-02-12

6.  High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza.

Authors:  Kelvin K W To; Anna J X Zhang; Ivan F N Hung; Ting Xu; Whitney C T Ip; Rebecca T Y Wong; Joseph C K Ng; Jasper F W Chan; Kwok-Hung Chan; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2012-05-09

Review 7.  Avian influenza A H5N1 virus: a continuous threat to humans.

Authors:  Kelvin Kw To; Kenneth Hl Ng; Tak-Lun Que; Jacky Mc Chan; Kay-Yan Tsang; Alan Kl Tsang; Honglin Chen; Kwok-Yung Yuen
Journal:  Emerg Microbes Infect       Date:  2012-09-19       Impact factor: 7.163

8.  Low population serum microneutralization antibody titer against the predominating influenza A(H3N2) N121K virus during the severe influenza summer peak of Hong Kong in 2017.

Authors:  Houshun Zhu; Andrew C Y Lee; Can Li; Winger W N Mak; Yetta Y Chen; Kwok-Hung Chan; Anna J X Zhang; Wai-Fong Fung; Rui-Qi Zhang; Yim-Fong Fung; Rosana W S Poon; Joy-Yan Lam; Sidney Tam; Ivan F N Hung; Honglin Chen; Kwok-Yung Yuen; Kelvin K W To
Journal:  Emerg Microbes Infect       Date:  2018-03-06       Impact factor: 19.568

9.  Molecular evolutionary analysis of pH1N1 2009 influenza virus in Reunion Island, South West Indian Ocean region: a cohort study.

Authors:  Hervé Pascalis; Sarah Temmam; David A Wilkinson; Najla Dsouli; Magali Turpin; Xavier de Lamballerie; Koussay Dellagi
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

Review 10.  The epidemiological and public health research response to 2009 pandemic influenza A(H1N1): experiences from Hong Kong.

Authors:  Peng Wu; Benjamin J Cowling; Joseph T Wu; Eric H Y Lau; Dennis K M Ip; Hiroshi Nishiura
Journal:  Influenza Other Respir Viruses       Date:  2012-08-09       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.